MediWound Ltd. (NASDAQ:MDWD)
| Market Cap | $175.45M-25.0% |
| Revenue (ttm) | $10.01M-52.2% |
| Net Income | -$23.51M-14.1% |
| EPS | -$1.82+4.1% |
| Shares Out | 12.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 187,835 |
| Open | $13.58 |
| Previous Close | $13.54 |
| Day's Range | $13.41 - $13.63 |
| 52-Week Range | $11.80 - $19.70 |
| Beta | 0.14 |
| Analysts | Buy |
| Price Target | $28.50(+109.71%) |
| Earnings Date | Mar 4, 2027 |
About MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd. Stock Analysis — InsiderScore
MediWound Ltd. scored higher than 4% of companies evaluated by InsiderBuying, and ranked 94th out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at MediWound Ltd. bought $6.6K of stock across 1 purchase in the last 90 days, the largest of them $6.6K.
None of these purchases could be measured against an existing holding, so this part of the factor scores on dollars alone.
1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 4, 2027Earnings report
$MDWD stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MDWD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MDWD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MDWD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MDWD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MDWD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MDWD
| IWMiShares Russell 2000 ETF | $3.37M |
| IZRLARK Israel Innovative Technology ETF | $1.81M |
| IWOiShares Russell 2000 Growth ETF | $1.25M |
| VTWOVanguard Russell 2000 ETF | $801.62K |
| IWCiShares Micro-Cap ETF | $418.48K |
| IWViShares Russell 3000 ETF | $187.38K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from MDWD’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 revenue miss and net loss offset by NexoBrid momentum and EscharEx Phase III progress indicating pipeline strength.
Recent Insider Activity
Insider Score Trend Over Time
+32.6 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
